Fitalite | 2014 Green tea in transdermal formulation: HPLC method for quality control and In Vitro drug release assays Campos Alves M, Aparecida de Almeida P, Polonini HC, Raposo NRB, de Oliveira Ferreira A, Brandao MAF Quimica Nova, 37(4), 728-735 RP-HPLC based analytical method for use in both quality control of green tea in a semisolid formulation and for in vitro drug release assays was developed and validated. The data showed that EGCG will be able to exert its systemic activity when delivered though the transdermal formulation. Read more SEE PRODUCT
Pentravan | 2014 Transdermal formulations containing human sexual steroids: Development and validation of methods and In Vitro drug release Polonini HC, Soldati PP, Leal de Oliveira MA, Brandao MAF, Chaves MGM, Raposo NRB Quimica Nova, 37(4), 720-727 In vitro release of bioidentical hormones in four different liposomal transdermal emulsions (containing testosterone, progesterone, estradiol, or estradiol and estriol) was assessed. The emulsions employed were found to be effective as transporting candidates for the efficient release of hormones in the transdermal delivery of human sexual steroids Read more SEE PRODUCT
Pentravan | 2014 Evaluation of percutaneous absorption performance for human female sexual steroids into Pentravan® Cream Polonini HC, Brandao MAF, Ferreira AO, Ramos C, Raposo NRB International Journal of Pharmaceutical Compounding, 18(4), 332-340 The purpose of this study was to evaluate the permeation potential of Pentravan. According to the results, human female sexual hormones incorporated in the oil-in-water vanishing cream base and applied topically are expected to exert their biological activities systemically with good efficacy due to their satisfactory permeation through human skin. Read more SEE PRODUCT
Pentravan | 2014 In vitro drug release and Ex Vivo percutaneous absorption of Resveratrol cream using HPLC with zirconized silica stationary phase Polonini HC, de Almeida Bastos C, Leal de Oliveira MA, Azevedo da Silva CG, Hollingworth Collins C, Fernandes Brandao MA, Rezende Barbosa Raposo N Journal of Chromatography B, 947-948, 23-31 The aim of this study was to establish the profile of resveratrol permeability into and across human skin. The results show that a person using a 1g dose containing 20 mg of resveratrol will (theoretically) have 12.53 mg of it liberated into his bloodstream, gradually and continuously for 24 h. Read more SEE PRODUCT
Syrspend SF | 2013 Stability of Rifampin in SyrSpend® SF Sorenson B, Whaley P International Journal of Pharmaceutical Compounding, 17(2), 162-164 The objective of this study was to determine the stability of rifampin (25mg/ml) in SyrSpend SF. Based on data collected, the beyond-use date of the preparation is at least 60 days when refrigerated or stored at room temperature and protected from light. Read more SEE PRODUCT
Syrspend SF | 2013 Stability of Midazolam in SyrSpend® SF and SyrSpend® SF Cherry Geiger CM, Sorenson B, Whaley PA International Journal of Pharmaceutical Compounding, 17(4), 344-346 The objective of this study was to determine the stability of midazolam in SyrSpend SF and SyrSpend SF Cherry suspending agents. Based on the data collected, the beyond-use date of these preparations is at least 58 days when protected from light at both refrigerated and room temperature storage conditions. Read more SEE PRODUCT
Syrspend SF | 2013 Stability of Captopril in SyrSpend® SF Geiger CM, Sorenson B, Whaley PA International Journal of Pharmaceutical Compounding, 17(4), 336-338 The objective of this study was to determine the stability of captopril (0.8mg/ml) in SyrSpend SF suspending agent. Based on the data collected, the beyond-use date of these preparations is 14 days when protected from light and refrigerated. Read more SEE PRODUCT
Pentravan | 2013 Pulsatile administration of Testosterone by the vaginal route using Pentravan® Maia H jr, Haddad C, Maia R, França CE, Casoy J Proceedings, online In the present study, testosterone was administered in the vulval/vaginal region at a dose of 3 mg/ml dissolved in a Pentravan®. An improvement in sexuality and the sensation of well-being was reported by 88% of the patients. There was also a positive effect on vaginal atrophy. Read more SEE PRODUCT
Syrspend SF | 2012 Stability of Propranolol Hydrochloride in SyrSpend® SF Geiger CM, Voudrie MA 2nd, Sorenson B International Journal of Pharmaceutical Compounding, 16(6), 513-515 The objective of this study was to determine the stability of propranolol hydrochloride in SyrSpend SF. Based on the data collected, when protected from light at room temperature, the beyond-use date of propranolol hydrochloride in SyrSpend SF was shown to be at least 90 days. Read more SEE PRODUCT
Syrspend SF | 2012 Stability of Omeprazole in SyrSpend® SF Alka (Reconstituted) Whaley PA, Voudrie MA 2nd, Sorenson B International Journal of Pharmaceutical Compounding, 16(2), 164-166 The objective of this study was to determine the stability of omeprazole 2mg/ml in SyrSpend® SF Alka (for reconstitution). The shelf life of this product is at least 92 days, based on data collected when refrigerated and protected from light. Read more SEE PRODUCT